CD24 expression is an independent prognostic marker in cholangiocarcinoma

Journal of Gastrointestinal Surgery

Volumn 11, Issue 4, 2007, Pages 445-451

  Agrawal, Shefali ^a   Kuvshinoff, Boris W ^a   Khoury, Thaer ^b   Yu, Jihnhee ^a   Javle, Milind M ^a   Levea, Charles ^b   Groth, Jeff ^b   Coignet, Lionel J ^a   Gibbs, John F ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

CD24 expression; Cholangiocarcinoma; Survival

Indexed keywords

CD24 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT TUMOR; FEMALE; HUMAN; INTRAHEPATIC BILE DUCT; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS;

ADULT; AGED; ANTIGENS, CD24; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34250686206     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-007-0091-5     Document Type: Article

References (41)

1. Burke EC, Jarnagin WR, Hochwald SN, Pisters PW, Fong Y, Blumgart LH. Hilar cholangiocarcinoma: patterns of spread, importance of hepatic resection for curative operation and a presurgical clinical staging system. Ann Surg 1998;228:385-394.
2. Nagorney DM, Donohue JH, Farnell MB, Schleck CD, Ilstrup DM. Outcomes after curative resections of cholangiocarcinoma. Arch Surg 1993;128(8):871-877.
3. Klempnauer J, Rideer GJ, von Wasielewski R, Werner M, Weimann A, Pichmayr R. Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J Clin Oncol 1997;15(3):947-954.
4. Abdel Wahab M, Fathy O, Elghwalby N, Sultan A, Elebidy E, Abdalla T, Elshobary M, Mostafa M, Foad A, Kandeel T, Abdel Raouf A, Salah T, Abu Zeid M, Abu Elenein A, Gad Elhak N, ElFiky A, Ezzat F. Resectability and prognostic factors after resection of hilar cholangiocarcinoma. Hepatogastroenterology 2006;53(67):5-10.
5. Ebata T, Nagino M, Kamiya J, Uesaka K, Nagasaka T, Nimura Y. Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg 2003;238(5):720-727.
6. Shirabe K, Shimada M, Tsujita E et al. Prognostic factors in node-negative intrahepatic cholangiocarcinoma with special reference to angiogenesis. Am J Surg 2004;187(4):538-542.
7. Abou-Rebyeh H, Al-Abadi H, Jonas S, Rotter I, Bechstein WO, Neuhaus P. DNA analysis of cholangiocarcinoma cells: prognostic and clinical importance. Cancer Detect Prev 2002;26(4):313-319.
8. Su MC, Hsu C, Kao HL, Jeng YM, CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma. Cancer Lett 2006;235(1):34-349.
9. Xiao M, Zhou NX, Huang ZQ, Lu YL, Chen LH, Wang DJ, Chang WL. The ratio of MMP-2 to TIMP-2 in hilar cholangio-carcinoma: a semi-quantitative study. Hepatobiliary Pancreat Dis Int 2004;3(4):599-602.
10. Hamamoto Y, Niino K, Ishiyama H, Hosoya T. Impact of pretreatment cholinesterase level on survival of inoperable intrahepatic or hepatic-hilar carcinomas treated with three-dimensional conformal radiotherapy. Radiat Med 2004;22(5):316-323.
11. Shibahara H, Tamada S, Higashi M, Goto M, Batra SK, Imai K, Yonezawa S. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology 2004;39 (1):220-229.
12. Sugimachi K, Aishima S, Taguchi K, Tanaka S, Shimada M, Kajiyama K, Sugimachi K, Tsuneyoshi M. The role of overexpression and gene amplification of cyclin Dl in intrahepatic cholangiocarcinoma. J Hepatol 2001;35(1):74-79.
13. Park BK, Paik YH, Park JY, Park KH, Bang S, Park SW, Chung JB, Park YN, Song SY. The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma. Am J Clin Oncol 2006;29(2): 138-142.
14. Fiorentino M, Altimari A, D'Errico A, Gabusi E, Chieco P, Masetti M, Grigioni WF. Low p27 expression is an independent predictor of survival for patients with either hilar or peripheral intrahepatic cholangiocarcinoma. Clin Cancer Res 2001;7 (12):3994-3999.
15. Tannapfel A, Engeland K, Weinans L, Katalinic A, Hauss J, Mossner J, Wittekind C, Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver. Br J Cancer 1999;80 (7): 1069-1074.
16. Weichert W, Denkert C, Burkhardt M, Gansukh T, Bellach J, Altevogt P, Dietel M, Kristansen G. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 2005;! 1(18):6572-6581.
17. Lim SC, Oh SH. The role of CD24 in various human epithelial neoplasias. Pathol Res Pract 2005;201(7):479-86.
18. Kristiansen G, Schluns K, Yongwei Y, Denkert C, Dietel M, Petersen I. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Brit J Cancer 2003;88:231-236.
19. Kristiansen G, Pilarsky C, Pervan J, Sturzebecher B, Stephan C, Jung K, Loening S, Rosenthal A, Dietel M. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 2004;58:183-192,
20. Kristiansen G, Denkert C, Schluns K, Dahl E, Pilarsky C, Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 2002;161(4):1215-1221.
21. Kristiansen G, Winzer KJ, Mayordomo E, Bellach J, Schluns K, Denkert C, Dahl E, Pilarsky C, Altevogt P, Guski H, Dietel M. CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 2003;9;4906-4913.
22. Pirrucello SJ, LeBien TW. The human B cell-association antigen CD24 is a single chain sialoglycoprotein. J Immunol 1986; 136:3779-3784.
23. Fischer GF, Majdic O, Gadd S, Knapp W. Signal transduction in lymphocytic and myeloid cells via CD24, a new member of phosphoinositol-anchored membrane molecules. J Immunol 1990;144:638-641.
24. Akashi T, Shirasawa T, Hirokawa K. Gene expression of CD24 core polypeptide molecule in normal rat tissues and human tumor cell lines. Virchows Arch 1994;425:399-406.
25. Aigner S, Ruppert M, Hubbe M, Sammar M, Sthoeger Z, Butcher EC, Vestweber D, Altevogt P. Heat stable antigen (mouse CD24) supports myeloid cell binding to endothelial and platelet P-selectin. Int Immunol 1995;7(10):1557-1565.
26. Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn J, Ruppert M, Zeller Y, Vestweber D, Stahel R, Sammar M, Altevogt P. CD24 a mucin-type glycoprotein is a ligand for P-selectin on human tumor cells. Blood 1997;89(9):3385-3395.
27. Aigner S, Ramos CL, Hafezi-Moghadam A, Lawrence MB, Friederichs J, Altevogt P, Ley K. CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J 1998;12(12):1241-1251.
28. Friederichs J, Zeller Y, Hafezi-Moghadam A, Grone HJ, Ley K, Altevogt P. The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. Cancer Res 2000;60 (23):6714-6722.
29. Taguchi T, Kiyokawa N, Mimori K, Suzuki T, Sekino T, Nakajima H, Saito M, Katagiri YU, Matsuo N, Matsuo Y, Karasuyama H, Fujimoto J. Pre-B cell antigen receptor-mediated signal inhibits CD24-induced apoptosis in human pre-B cells. J Immunol 2003;170(1):252-260.
30. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda R, Bedolla R, Kreisberg JI. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002;8:1168-1171.
31. Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T, Yaqita H, Sleeman JP. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res 2005;65(23):10783-10793.
32. Smith SC, Oxford G, Wu Z, Nitz MD, Conaway M, Frierson HF, Hampton G, Theodorescu D. The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res 2006;66(4):1917-1922.
33. Javle MM, Yu J, Khoury T. AKT expression may predict favorable prognosis in cholangiocarcinoma. J Gastroenterol Hepatol 21:1744-1751.
34. Uckun FM, Song CW. Lack of CD24 antigen expression in B-lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blasts. Blood 1993;81 (5): 1323-1332.
35. Weber E, Schmitter D, Resch H, Zarn JA, Waibel R, Mabry M, Huquenin P, Stahel RA, Radiation studies on B cell differentiation marker CD24/SCLC Cluster-4 antigen expressing and non-expressing lung cancer cell lines and mouse fibroblasts. Int J Radiat Biol 1995;68(2):205-213.
36. Nordsmark M, Overgaard J. Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. Acta Oncol 2004;43(4):396-403.
37. Rofstad EK, Sundfor K, Trope CG, Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer 2000;83(3): 354-359.
38. Yokoi K, Fidler IJ. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 2004;10(7):2299-2306.
39. Koch S, Mayer F, Honecker F, Schittenhelm M, Bokemeyer C. Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro. Br J Cancer 2003;89(11):2133-2139.
40. Scheurer SB, Rybak JN, Rosli C, Neri D, Elia G. Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: a transcriptomic and proteomic study. Proteomics 2004;4:1737-1760.
41. Pitt HA, Nakeeb A, Abrams RA et al. Perihilar cholangiocarcinoma: postoperative radiotherapy does not improve survival. Ann Surg 1995;221(6):788-798.